RedHill Biopharma Reports First Quarter 2021 Financial Results and Operational HighlightsPRNewsWire • 05/27/21
RedHill Biopharma receives two US Patent and Trademark Office Allowances for its oral pills for COVID-19, opaganib and RHB-10Proactive Investors • 05/26/21
RedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19PRNewsWire • 05/26/21
RedHill Biopharma Presents Analyses of Movantik Onset of Action and Symptom Improvement at DDW 2021PRNewsWire • 05/24/21
RedHill Biopharma Presents a New Travelers' Diarrhea Clinical Severity Classification Tool and its Use in Aemcolo Efficacy Analysis at DDW 2021PRNewsWire • 05/21/21
RedHill Biopharma to Host First Quarter 2021 Financial Results and Operational Highlights Webcast on May 27, 2021PRNewsWire • 05/20/21
RedHill Biopharma's Phase 2/3 COVID-19 Study of Opaganib Passes Fourth DSMB Review with Unanimous Recommendation to ContinuePRNewsWire • 04/09/21
RedHill Biopharma announces resolution to patent litigation in the US in response to a generic version of MovantikProactive Investors • 03/26/21
RedHill Biopharma Announces Settlement of Movantik® Patent Litigation with MSN PharmaceuticalsPRNewsWire • 03/25/21
RedHill Biopharma provides opaganib treatment under compassionate use exemption for several Swiss patients suffering from coronavirus pneumoniaProactive Investors • 03/22/21
RedHill Biopharma Announces Compassionate Use Treatment with Opaganib of first COVID-19 Patients in SwitzerlandPRNewsWire • 03/22/21
RedHill Biopharma Ltd. (RDHL) CEO Dror Ben-Asher on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 03/18/21
RedHill Biopharma delivers revenue growth, commercial expansion and pipeline progress in FY2020 results as focused efforts pay offProactive Investors • 03/18/21
RedHill Biopharma Provides Fourth Quarter and Full Year 2020 Financial Results and Operational HighlightsPRNewsWire • 03/18/21
RedHill Biopharma to Host Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights Webcast on March 18, 2021PRNewsWire • 03/11/21
RedHill Biopharma Announces Closing of $35 Million Bought Deal Offering of American Depositary SharesPRNewsWire • 03/04/21
RedHill Biopharma Increases Previously Announced Bought Deal to $35 Million of American Depositary SharesPRNewsWire • 03/02/21
RedHill Biopharma Announces $10 Million Bought Deal Offering of American Depositary SharesPRNewsWire • 03/01/21